JPH09501912A - 不活性化レスピラトリーシンシシャルウイルスワクチン - Google Patents
不活性化レスピラトリーシンシシャルウイルスワクチンInfo
- Publication number
- JPH09501912A JPH09501912A JP7506123A JP50612395A JPH09501912A JP H09501912 A JPH09501912 A JP H09501912A JP 7506123 A JP7506123 A JP 7506123A JP 50612395 A JP50612395 A JP 50612395A JP H09501912 A JPH09501912 A JP H09501912A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- immunogenic
- inactivated
- sample
- infectious
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18551—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.細胞および血清成分を実質的に含まず、非感染性、非免疫増強性、免疫原性 かつ防御性である精製、不活性化RSウイルスおよびそのキャリヤーを含み、こ れを用いて免疫化したホスト中にレスピラトリーシンシシャル(RS)ウイルス 特異性免疫反応を起こさせることができる免疫原性組成物。 2.RSウイルスにより誘発される疾患からヒトを防御するためのヒト・ホスト に対して生体内投与するためのワクチンとして製剤された請求項1記載の組成物 。 3.上記のキャリヤーがさらにアジュバントを含む、請求項2記載の組成物。 4.注射剤、鼻腔経由、経口または粘膜表面に投与するように製剤された、請求 項2記載の組成物。 5.細胞株上でRSウイルスを増殖させて増殖ウイルスを生産し、 上記のウイルスを採取して採取ウイルスを取得し、 上記の採取ウイルスを非変性条件下で精製して細胞および血清成分を実質的に 含まない精製ウイルスを調製し、 不活性化剤を用いて上記の精製ウイルスを不活性化して非感染性、非免疫増強 性かつ免疫原性RSウイルスを調製し、かつ 上記の非感染性、非免疫増強性かつ免疫原性RSウイルスを上記の免疫原性組 成物として製剤する ことを含む、これを用いて免疫化したホスト中にレスピラトリーシンシシャル( RS)ウイルス特異性免疫反応を起こさせることができる非免疫増強性、免疫原 性組成物の製造方法。 6.上記の不活性化剤がβ−プロピオラクトンである、請求項5記載の方法。 7.上記の不活性化剤が非イオン性界面活性剤である、請求項5記載の方法。 8.上記の非イオン性界面活性剤が、n−オクチル−α−D−グルコピラノシド およびn−オクチル−β−D−グルコピラノシドのいずれかである、請求項7記 載の方法。 9.上記の不活性化剤がアスコルビン酸である、請求項5記載の方法。 10.上記の細胞株がワクチン品質の連続細胞株である、請求項5記載の方法。 11.上記の連続細胞株がVERO細胞株である、請求項10記載の方法。 12.上記の精製ステップが、細胞砕片を除くための精密ろ過、血清成分を除く ための接線流限外ろ過、さらに血清成分を除くための超遠心分離による精密ろ過 物のペレット化、およびペレット化物質をスクロース 密度勾配遠心分離で処理して行われる、請求項5記載の方法。 13.上記の接線流限外ろ過が、名目分子量約100〜約300kDaカットオ フ膜を用いて行われる、請求項12記載の方法。 14.上記の精製ステップが、細胞砕片を除くための精密ろ過、血清成分を除く ための接線流限外ろ過、さらに血清成分を除くためのゲルろ過、およびさらに血 清成分を除くためのイオン交換クロマトグラフィーにより行われる、請求項5記 載の方法。 15.請求項1記載の免疫原性組成物の有効量をホストに投与することから成る レスピラトリーシンシシャルウイルスにより起きる疾患に対してヒトを免疫化す る方法。 16.上記のホストが、幼児、小児、妊婦、出産期の女性、老人、免疫無防備状 態の個体、およびその他の感受性が高い個人のいずれかである、請求項15記載 の方法。 17. (a)試料を請求項1記載の免疫原性組成物と接触させて、非感染性、 非免疫増強性かつ免疫原性RSウイルスおよびこれと特異的に反応性の試料中に 存在するあらゆる抗体から成る複合体を生成させ、かつ (b)複合体の生成を測定する ステップから成る試料中のレスピラトリーシンシシャル(RS)ウイルスタンパ クと特異的に反応性の上記の抗体の存在の測定方法。 18. (a)RSウイルス防御に特異的な抗体を生成させるために請求項1記 載の免疫原性組成物を用いて対象を免疫化し、 (b)試料を抗体と接触させ、試料内に存在するあらゆるRSウイルスタンパ クと上記のRSウイルスタンパク特異性抗体から成る複合体を生成させ、かつ (c)複合体の生成を測定する ステップから成る試料中のレスピラトリーシンシシャル(RS)ウイルスタンパ クの存在の測定方法。 19. (a)請求項1記載の免疫原性組成物、 (b)非感染性、非免疫増強性かつ非免疫原性RSウイルスを試料と接触させ 、非感染性、非免疫増強性かつ免疫原性RSウイルスおよび試料中に存在するあ らゆる抗体から成る組成物を生成するための手段、 (c)複合体の生成を測定する手段 から成る、RSウイルスタンパクと特異的に反応する上記の試料中の抗体の存在 を測定するための診断キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10274293A | 1993-08-06 | 1993-08-06 | |
US08/102,742 | 1993-08-06 | ||
PCT/CA1994/000425 WO1995004545A1 (en) | 1993-08-06 | 1994-08-04 | Inactivated respiratory syncytial viral vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09501912A true JPH09501912A (ja) | 1997-02-25 |
JP4053587B2 JP4053587B2 (ja) | 2008-02-27 |
Family
ID=22291469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50612395A Expired - Fee Related JP4053587B2 (ja) | 1993-08-06 | 1994-08-04 | 不活性化レスピラトリーシンシシャルウイルスワクチン |
Country Status (15)
Country | Link |
---|---|
US (1) | US7083795B1 (ja) |
EP (1) | EP0714306B1 (ja) |
JP (1) | JP4053587B2 (ja) |
KR (1) | KR100402379B1 (ja) |
CN (1) | CN1103603C (ja) |
AT (1) | ATE164313T1 (ja) |
AU (1) | AU677090B2 (ja) |
BR (1) | BR9407182A (ja) |
CA (1) | CA2167274C (ja) |
DE (1) | DE69409243T2 (ja) |
DK (1) | DK0714306T3 (ja) |
ES (1) | ES2113670T3 (ja) |
GR (1) | GR3026619T3 (ja) |
RU (1) | RU2142817C1 (ja) |
WO (1) | WO1995004545A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021531820A (ja) * | 2018-07-06 | 2021-11-25 | シァメン・ユニヴァーシティ | 呼吸器合胞体ウイルスを不活化して保存する方法 |
JP2023501693A (ja) * | 2019-12-10 | 2023-01-18 | レプリゲン・コーポレーション | ウイルスベクターの調製方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4243491A1 (de) * | 1992-12-22 | 1994-06-23 | Behringwerke Ag | Verfahren zur Reinigung und Anreicherung von Rubella-Virus |
CN106008716B (zh) * | 2010-07-07 | 2019-08-13 | 人工细胞科技公司 | 呼吸道合胞病毒抗原组合物和方法 |
WO2019121846A1 (en) * | 2017-12-19 | 2019-06-27 | CSL Behring Lengnau AG | Protein purification and virus inactivation with alkyl glycosides |
KR20210018206A (ko) | 2018-04-03 | 2021-02-17 | 사노피 | 항원성 호흡기 세포융합 바이러스 폴리펩타이드 |
WO2022159632A1 (en) | 2021-01-20 | 2022-07-28 | Alto Neuroscience, Inc. | Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA814386B (en) * | 1980-07-01 | 1982-07-28 | Nat Res Dev | Production of viral antigens |
US4591505A (en) * | 1982-04-14 | 1986-05-27 | New York Blood Center, Inc. | Process for inactivating hepatitis B virus |
US4664912A (en) | 1984-10-01 | 1987-05-12 | Wiktor Tadeusz J | Process for the large scale production of rabies vaccine |
US4790987A (en) | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
EP0310317B1 (en) * | 1987-09-28 | 1993-12-15 | Beecham Inc. | Inactivation of viruses and bacteria |
US5200179A (en) * | 1987-09-28 | 1993-04-06 | Beecham Group P.L.C. | Vaccine |
US5223254A (en) * | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
GB8914968D0 (en) | 1989-06-29 | 1989-08-23 | Connaught Lab | Production of virus and purification of viral envelope proteins for vaccine use |
IL105456A (en) | 1992-04-21 | 1996-12-05 | American Home Prod | Vaccines of attenuated respiratory syncytial virus |
-
1994
- 1994-08-04 BR BR9407182A patent/BR9407182A/pt not_active Application Discontinuation
- 1994-08-04 CA CA002167274A patent/CA2167274C/en not_active Expired - Fee Related
- 1994-08-04 JP JP50612395A patent/JP4053587B2/ja not_active Expired - Fee Related
- 1994-08-04 WO PCT/CA1994/000425 patent/WO1995004545A1/en active IP Right Grant
- 1994-08-04 DE DE69409243T patent/DE69409243T2/de not_active Expired - Lifetime
- 1994-08-04 RU RU96105905A patent/RU2142817C1/ru not_active IP Right Cessation
- 1994-08-04 KR KR1019960700607A patent/KR100402379B1/ko not_active IP Right Cessation
- 1994-08-04 US US08/583,124 patent/US7083795B1/en not_active Expired - Fee Related
- 1994-08-04 DK DK94923619T patent/DK0714306T3/da active
- 1994-08-04 AT AT94923619T patent/ATE164313T1/de active
- 1994-08-04 EP EP94923619A patent/EP0714306B1/en not_active Expired - Lifetime
- 1994-08-04 CN CN94193703A patent/CN1103603C/zh not_active Expired - Lifetime
- 1994-08-04 AU AU73801/94A patent/AU677090B2/en not_active Ceased
- 1994-08-04 ES ES94923619T patent/ES2113670T3/es not_active Expired - Lifetime
-
1998
- 1998-04-10 GR GR980400815T patent/GR3026619T3/el unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021531820A (ja) * | 2018-07-06 | 2021-11-25 | シァメン・ユニヴァーシティ | 呼吸器合胞体ウイルスを不活化して保存する方法 |
JP2023501693A (ja) * | 2019-12-10 | 2023-01-18 | レプリゲン・コーポレーション | ウイルスベクターの調製方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0714306B1 (en) | 1998-03-25 |
DE69409243D1 (de) | 1998-04-30 |
AU677090B2 (en) | 1997-04-10 |
KR100402379B1 (ko) | 2004-03-24 |
EP0714306A1 (en) | 1996-06-05 |
RU2142817C1 (ru) | 1999-12-20 |
ATE164313T1 (de) | 1998-04-15 |
ES2113670T3 (es) | 1998-05-01 |
US7083795B1 (en) | 2006-08-01 |
WO1995004545A1 (en) | 1995-02-16 |
CN1103603C (zh) | 2003-03-26 |
DK0714306T3 (da) | 1998-10-19 |
JP4053587B2 (ja) | 2008-02-27 |
CA2167274C (en) | 2007-11-27 |
AU7380194A (en) | 1995-02-28 |
CA2167274A1 (en) | 1995-02-16 |
KR960703618A (ko) | 1996-08-31 |
BR9407182A (pt) | 1996-09-17 |
DE69409243T2 (de) | 1998-08-06 |
CN1133013A (zh) | 1996-10-09 |
GR3026619T3 (en) | 1998-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Murphy et al. | Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity | |
JP3734263B2 (ja) | 呼吸器シンシチウムウイルスに対するワクチンのためのアジュバント | |
KR102118458B1 (ko) | 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들 | |
US6309649B1 (en) | Subunit respiratory syncytial virus vaccine preparation | |
JP3602448B2 (ja) | 核酸呼吸器シンシチウムウイルスワクチン | |
JP2007031452A (ja) | Rsvサブユニット成分およびインフルエンザウイルス調製物を含む多価免疫原性組成物 | |
Carlsson et al. | Secretory and serum immunoglobulin class-specific antibodies to poliovirus after vaccination | |
JPH11513372A (ja) | パラインフルエンザウイルスの糖タンパクおよびワクチン | |
Brandt et al. | Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na | |
CN1355710A (zh) | 抗肺炎链球菌和呼吸道合胞病毒(rsv)的联合疫苗 | |
US20120107353A1 (en) | Composition | |
JPH04502410A (ja) | ウイルスの生産およびワクチン使用のためのウイルスエンベロープタンパク質の精製 | |
van Wyke Coelingh et al. | Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus | |
JP4053587B2 (ja) | 不活性化レスピラトリーシンシシャルウイルスワクチン | |
Kasel et al. | Human influenza: aspects of the immune response to vaccination | |
US7223410B1 (en) | Inactivated respiratory syncytial viral vaccines | |
CA2518924C (en) | Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv | |
US20020136739A1 (en) | Subunit respiratory syncytial virus preparation | |
US20060110740A1 (en) | Use of sendai virus as a human parainfluenza vaccine | |
WO2024196683A2 (en) | Vsv-based sars-cov-2 vaccine candidates and igy antibodies as prophylactic and therapeutic agents against sars-cov-2 and variants of concern | |
CN117323423A (zh) | 一种重组呼吸道合胞病毒疫苗及其制备方法和应用 | |
VANKIRK et al. | SIGNIFICANCE OF LOCAL RESPIRATORY TRACT ANTIBODY TO RESPIRATORY SYNCYTIAL VIRUS JOHN MILLS, MD HARRY LS KNOPF, MD |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20040706 |
|
RD14 | Notification of resignation of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7434 Effective date: 20040706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051129 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060228 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060529 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070619 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20070726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070919 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071206 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101214 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |